Experiments

Searchable full-text extractions: founding hypothesis, core claims, experimental setups, key results and statistics — pulled out of each paper as structure. Search a cell line, an assay or an entity (e.g. HUH7) and find every paper that worked with it. This corpus stands on its own: most entries carry no reproduction assessment (yet).

• Vitamin C Conditioning Generates Tumor-Targeting CAR T Cells with Superior Cytotoxicity and Fitness in a Posttransplant Lymphoproliferative Disorder Tumor Model.

  PMID 41416402 · PMC13136873 · Molecular cancer therapeutics · 2026 · 8 claims · 8 setups

  Full-text index only

  VitC conditioning enhances transduction efficiency and proliferative capacity, yielding a higher yield of CD4+ and CD8+ CAR19-Ts

  cd3+ je6-1 car19-ts coculture flow nf-κb cytotoxicity

• Single-immunocyte transcriptomics reveal the role of natural killer cell-dependent exogenous antigen presentation in ankylosing spondylitis severity.

  PMID 41593306 · PMC12868835 · Experimental & molecular medicine · 2026 · 8 claims · 8 setups

  Full-text index only

  Innate antibacterial defense functions are generally enhanced in most cell types at AS onset and are negatively associated with AS severity

  pbmcs gwas pbmc-derived cd4+ single-cell bulk mendelian

• Metabolic quiescence of naive-like memory T cells precedes and maintains antigen-specific T cell memory.

  PMID 41735532 · PMC12956582 · Nature immunology · 2026 · 8 claims · 8 setups

  Full-text index only

  CD8+ T cells upregulate glycolysis to fuel anabolic needs for proliferation but predominantly use oxidative phosphorylation (OXPHOS) for energy production during the acute phase (days 7-28) after YFV vaccination

  peripheral cd8+ ns4b+ antigen-specific flow scrna-seq cite-seq

• Neoadjuvant sintilimab plus chemotherapy in EGFR-mutant NSCLC: Phase 2 trial interim results (NEOTIDE/CTONG2104).

  PMID 38897205 · PMC11293361 · Cell reports. Medicine · 2024 · 8 claims · 8 setups

  Has reproduction · 72

  Neoadjuvant sintilimab plus carboplatin/nab-paclitaxel is clinically feasible and tolerable in resectable EGFR-mutant NSCLC, with all 18 patients completing treatment and undergoing radical surgery.

  pre resected tumor serial whole-exome bulk single-cell

• PD-1 and TIGIT coexpression identifies a circulating CD8 T cell subset predictive of response to anti-PD-1 therapy.

  PMID 33188038 · PMC7668369 · Journal for immunotherapy of cancer · 2020 · 7 claims · 6 setups

  Has reproduction · 75

  The frequency of circulating PD-1+TIGIT+ (DPOS) CD8+ T cells after 1 month of anti-PD-1 therapy is associated with clinical response and overall survival

  pbmcs sorted expanded cancer multiparameter receptor targeted

• α4 Integrin blockade impairs CD8+ T cell neuroimmune surveillance following SIV infection.

  PMID 41734020 · PMC13078879 · The Journal of clinical investigation · 2026 · 8 claims · 8 setups

  Full-text index only

  α4 blockade preserves CD4+ Th1 cell access to brain parenchyma but impairs CD8 effector recruitment, disrupting antiviral control

  siv-infected live macaque cd4-δitga4 flow antibody single-cell